Prognosis Symptoms, Quality of Life and Comorbidity Relationship with Cough in Patients with Idiopathic Pulmonary Fibrosis

Abstract

Objective: Cough is one of the most frequent symptoms in patients with idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate whether there was any difference with respect to quality of life, depression, sleep disturbance and reflux symptoms between IPF patients with and without cough symptom. Study Design: Cross-sectional study Materials and Methods: Patients with IPF who were admitted to outpatient clinic were divided into two groups according to the Visual Analog Scale (VAS) scores as cough group and non- cough group. In each group, Leicester cough questionnaire, reflux questionnaire, Beck depression questionnaire, St George's quality of life questionnaire (SGRQ) and Sleep Quality index were evaluated to determine whether there were any differences between groups. Results: It was shown that the Leicester cough questionnaire score was lower in the cough group (86±24.9 vs 111±18.9) (p 0,02). Beck depression score revealed moderate level of depression in both groups (22±10.74 in cough group vs 18±11.86 in non-cough group) (p 0,4). SGRQ symptom score was significantly higher in the cough dominant group (p 0,04). Conclusion: It is found that presence of cough in patients with IPF negatively affected the quality of life and was associated with the sleep disorders and depression. Leicester cough questionnaire can be used to assess whether the cough symptom affects patients’ quality of life in routine clinical evaluation of patients with IPF. This evaluation is thought to improve quality of life and treatment compliance by increasing cough palliation in IPF patients.

Keywords

• Idiopathic pulmonary fibrosis
• Cough
• Leicester cough questionnaire
• Quality of life

References

1. American Thoracic Society; European Respiratory Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 2000;161(2 Pt 1):646-664.
2. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8.
3. Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology. 2017;22(5):950-956.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
5. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
6. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377(9779):1760-1769.
7. Ryerson CJ, Abbritti M, Ley B, et al. Cough predic ts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16(6):969-975.
8. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-343.

9. Buysse DJ, Hall ML, Strollo PJ, et al. Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med. 2008;4(6):563-571.
10. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
11. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321-1327.
12. Ponce J, Garrigues V, Agreus L, et al. Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs usual primary care for GERD: Pooled analysis of five cluster-randomised European studies. Int J Clin Pract. 2012;66(9):897-905.
13. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-691.
14. Raghu G, Remy-Jardin M, Myers JL, et al; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST
15. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165(2):277-304.
16. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
17. Crystal RG, Fulmer JD, Roberts WC, et al. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976;85(6):769-788.
18. Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6:4.
19. Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med. 2005;11(5):412-416.
20. Kurhan F, Goktalay T, Havlucu Y, et al. The validity and reliability of the Turkish version of the Leicester Cough Questionnaire in COPD patients. Turk J Med Sci. 2018;48(4):811-816.
21. Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: A case series. Chest. 2006;129(3):794-800.
22. Selman M. A dark side of interferon-gamma in the treatment of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med. 2003;167(7):945-946.
23. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390-1394.
24. Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med. 2016;193(12):1345-1352.
25. Martinez TY, Pereira CA, dos Santos ML, et al. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest. 2000;117(6):1627-1632.
26. Cox IA, Borchers Arriagada N, de Graaff B, et al. Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Eur Respir Rev. 2020;29(158):200154. doi:10.1183/16000617.0154-2020
27. Naji NA, Connor MC, Donnelly SC, et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil. 2006;26(4):237-243.
28. Tzanakis N, Samiou M, Lambiri I, et al. Evaluation of health-related quality of life and dyspnea scales in patients with idiopathic pulmonary fibrosis: Correlation with pulmonary function tests. Eur J Intern Med. 2005;16(2):105-112.
29. Glaspole IN, Watson AL, Allan H, et al. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(2).
30. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440.
31. Rozanski C, Mura M. Multi-dimensional indices to stage idiopathic pulmonary fibrosis: A systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):8-18.
32. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-691.